IDEXX Laboratories, Inc.
- Open
- 535.93
- Day high
- 535.93
- Day low
- 518.55
- Prev close
- 535.93
- Volume
- 223K
- Mkt cap
- $41.3B
- P/E (TTM)
- 38.3
- EPS (TTM)
- $13.67
- P/B
- 26.5
- P/S
- 9.3
- Yield
- —
- Per share
- —
IDEXX Laboratories, Inc. (IDXX) is a Healthcare company listed on NASDAQ. The stock is down 0% over the past year.
IDEXX Laboratories, Inc. (IDXX) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
IDXX earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $3.41 | $3.47 | +1.8% | $1.1B | +2.0% |
| Feb 2, 2026 | $2.93 | $3.08 | +5.1% | $1.1B | +1.7% |
| May 1, 2025 | $2.85 | $2.96 | +3.9% | $998M | +0.1% |
| Feb 3, 2025 | $2.39 | $2.62 | +9.6% | $954M | +2.0% |
| Oct 31, 2024 | $2.68 | $2.80 | +4.5% | $976M | -0.5% |
| May 1, 2024 | $2.67 | $2.81 | +5.2% | $964M | -0.0% |
| Nov 1, 2023 | $2.37 | $2.53 | +6.8% | $916M | -1.2% |
| May 2, 2023 | $2.42 | $2.55 | +5.4% | $900M | +0.9% |
| Feb 6, 2023 | $1.94 | $2.05 | +5.7% | $829M | +0.9% |
| Nov 1, 2022 | $2.04 | $2.15 | +5.4% | $842M | +1.4% |
| Aug 2, 2022 | $1.56 | $1.56 | +0.0% | $861M | -0.3% |
| May 4, 2022 | $2.26 | $2.27 | +0.4% | $837M | -0.1% |
IDXX insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 2, 2026 | FENNELL GEORGEofficer: Executive Vice President | Option | 639 | — |
| Jun 2, 2026 | FENNELL GEORGEofficer: Executive Vice President | Tax | 284 | $566.79 |
| May 14, 2026 | Kingsley Lawrence Ddirector | Grant | 234 | — |
| May 14, 2026 | SAMAD SAMdirector | Grant | 234 | — |
| May 14, 2026 | ESSIG STUARTdirector | Grant | 234 | — |
| May 14, 2026 | Peacock Karendirector | Grant | 525 | $533.92 |
| May 14, 2026 | Britt Irene Changdirector | Grant | 234 | — |
| May 14, 2026 | Vandebroek Sophie V.director | Grant | 525 | $533.92 |
| May 14, 2026 | Claflin Bruce L.director | Grant | 525 | $533.92 |
| May 14, 2026 | Kingsley Lawrence Ddirector | Grant | 525 | $533.92 |
| May 14, 2026 | Britt Irene Changdirector | Grant | 525 | $533.92 |
| May 14, 2026 | JUNIUS DANIEL Mdirector | Grant | 234 | — |
| May 14, 2026 | JUNIUS DANIEL Mdirector | Grant | 525 | $533.92 |
| May 14, 2026 | HOOLEY JOSEPH Ldirector | Grant | 234 | — |
| May 14, 2026 | SAMAD SAMdirector | Grant | 525 | $533.92 |
Source: IDXX SEC Form 4 filings, latest Jun 2, 2026. For informational purposes only — not investment advice.
See the full IDXX insider & 13F page →IDEXX Laboratories, Inc. company profile
Overview
IDEXX Laboratories, Inc. (NASDAQ:IDXX) is a leading global provider of veterinary diagnostics and water quality testing solutions founded in 1983 and headquartered in Westbrook, Maine. The company went public in 1991 and has grown to become the dominant player in companion animal veterinary diagnostics, serving veterinary clinics, reference laboratories, and water testing markets worldwide. IDEXX operates through four main segments: Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry and Dairy (LPD), and Other segments, with the companion animal business representing the vast majority of revenues and profits.
Business
IDEXX operates primarily in the veterinary diagnostics industry, which involves developing and manufacturing medical testing equipment and consumables that help veterinarians diagnose diseases and monitor the health of animals. The veterinary diagnostics market parallels human medical diagnostics but is specifically tailored for animal physiology and diseases. The company's core business revolves around four main segments: **Companion Animal Group (CAG) - approximately 85% of total revenue**: This segment provides diagnostic solutions for dogs, cats, and other pets treated at veterinary clinics. The CAG business includes point-of-care diagnostic instruments like Catalyst chemistry analyzers that test blood and urine samples in veterinary offices, SNAP rapid test kits that provide quick results for common conditions, and hematology analyzers like the ProCyte series that analyze blood cells. The segment also operates reference laboratories where veterinary samples are sent for more complex testing, and provides veterinary software solutions and practice management systems that help clinics operate more efficiently. **Water Quality Products - approximately 8% of total revenue**: This division manufactures testing products that detect harmful bacteria and microorganisms in water supplies. Key products include Colilert tests that detect E. coli and coliform bacteria, and specialized testing systems used by water utilities, environmental laboratories, and regulatory agencies to ensure water safety. **Livestock, Poultry and Dairy (LPD) - approximately 5% of total revenue**: This segment provides diagnostic tests and monitoring solutions for commercial animal agriculture, including tests for diseases that affect cattle, pigs, chickens, and other farm animals. **Other segments - approximately 2% of total revenue**: This includes human point-of-care diagnostics and biomedical research products, though these represent a small portion of the overall business. The veterinary diagnostics industry serves the growing pet healthcare market, which has expanded significantly as pet ownership has increased and pet owners increasingly view their animals as family members worthy of advanced medical care.
Revenue model
IDEXX generates revenue through multiple complementary business models that create recurring revenue streams and drive customer loyalty. **Product Sales and Consumables Model**: The company follows a "razor and blade" business model where it places diagnostic instruments in veterinary clinics and then generates ongoing revenue from consumable test kits, reagents, and supplies needed to operate those instruments. For example, when a clinic purchases a Catalyst chemistry analyzer, it must continually buy IDEXX's proprietary test slides and reagents to run patient samples. This creates predictable recurring revenue streams that typically grow over time as clinics increase their testing volume. **Reference Laboratory Services**: IDEXX operates a network of reference laboratories where veterinary clinics send samples for complex diagnostic testing that cannot be performed in-house. Clinics pay per test, and IDEXX benefits from economies of scale by centralizing sophisticated testing capabilities. This service model generates high-margin recurring revenue. **Software Subscriptions and Services**: The company provides cloud-based practice management software, diagnostic imaging systems, and digital health platforms on a subscription basis. These software solutions help veterinary practices operate more efficiently and often integrate with IDEXX's diagnostic equipment, creating switching costs for customers. **Factors that increase margins** include the company's dominant market position allowing for premium pricing, the recurring nature of consumable sales, economies of scale in manufacturing and R&D, and the mission-critical nature of diagnostics which makes demand relatively price-inelastic. Innovation in higher-value tests and automation also drives margin expansion. **Factors that could pressure margins** include increased competition from other diagnostic companies, economic downturns that reduce pet spending and veterinary visits, pricing pressure from large veterinary chains seeking volume discounts, rising raw material and labor costs, and potential regulatory changes affecting veterinary testing requirements. The company is also sensitive to foreign exchange fluctuations given its significant international operations.
Competitive moat
IDEXX possesses a substantial and durable competitive moat built on several reinforcing advantages that create high barriers to entry and switching costs for customers. The company's primary moat stems from its **installed base of diagnostic instruments** combined with proprietary consumables. Once a veterinary clinic invests in IDEXX equipment like Catalyst analyzers or SNAP test readers, they become locked into purchasing IDEXX's proprietary test kits and reagents. Switching to a competitor would require replacing expensive equipment and retraining staff, creating significant switching costs. With over 97% customer retention rates, this installed base provides predictable recurring revenue. **Network effects** strengthen the moat as IDEXX's reference laboratory network becomes more valuable with scale. The company can offer faster turnaround times, more specialized tests, and better economics as it processes more samples across its laboratory network. Veterinarians also benefit from IDEXX's integrated software ecosystem that connects in-clinic diagnostics with reference lab results and practice management systems. **Regulatory barriers and intellectual property** provide additional protection. Veterinary diagnostics require regulatory approvals and extensive validation studies, making it costly and time-consuming for new entrants to develop competing products. IDEXX holds numerous patents on its testing methodologies and instrument designs. **Brand strength and switching costs** are significant, as veterinarians develop familiarity with IDEXX's testing protocols and trust the accuracy of results. The mission-critical nature of diagnostic testing makes veterinarians reluctant to switch to unproven alternatives. However, the moat faces potential challenges from **large human diagnostics companies** like Abbott or Roche that could leverage their scale and R&D capabilities to enter veterinary markets. **Consolidation among veterinary chains** could also create more powerful buyers capable of negotiating better terms or demanding multi-vendor solutions. Additionally, **technological disruption** from new diagnostic approaches or point-of-care technologies could potentially bypass IDEXX's installed base advantages.
Risks & safety
IDEXX demonstrates a strong financial position with moderate margin of safety considerations: **Overall Assessment**: The company maintains solid financial health with strong cash generation, though trading at premium valuations typical of quality healthcare companies. **Liquidity and Solvency**: - Current ratio of 1.16, indicating adequate short-term liquidity - Cash and short-term investments of $164 million as of Q1 2025 - Strong operating cash flow of $238 million in Q1 2025 and $929 million for full year 2024 - Free cash flow of $208 million in Q1 2025 and $798 million for 2024 - Debt-to-equity ratio of 0.73, representing moderate leverage but manageable given cash generation **Valuation Metrics**: - P/E ratio of 35.2x based on Q1 2025 earnings, reflecting premium valuation - EV/EBITDA of 24.9x, indicating expensive valuation relative to earnings - Price-to-book ratio of 23.6x, suggesting significant premium to tangible assets - Graham number of $34.58 versus current price around $471, indicating overvaluation by traditional value metrics **Other Considerations**: - Consistent profitability with strong ROE of 16.8% - Predictable recurring revenue model provides earnings stability - Market leadership position offers some downside protection - High valuation leaves little room for execution missteps or market deterioration
Recent development
Over the past few years, IDEXX has pursued several key strategic initiatives focused on innovation, international expansion, and digital transformation of veterinary practices. **Product Innovation Pipeline**: The company has launched several breakthrough diagnostic products, most notably the IDEXX inVue Dx cellular analyzer in Q4 2024, which provides 3D cellular imaging and eliminates the need for traditional slide preparation in hematology testing. IDEXX is targeting over 4,500 placements of this advanced instrument in 2025. The company also introduced the IDEXX Cancer Dx panel for early detection of canine lymphoma, with plans to expand this to cover the six most prevalent canine cancers over the next three years. Additionally, IDEXX launched the Catalyst Pancreatic Lipase test to enhance its point-of-care chemistry testing capabilities. **Software and Digital Ecosystem Expansion**: IDEXX has significantly invested in cloud-based software solutions, including practice information management systems (PIMS) and the Vello pet owner engagement platform. These digital tools help veterinary practices improve efficiency, engage pet owners, and integrate seamlessly with IDEXX's diagnostic equipment. The veterinary software and diagnostic imaging segment has shown strong growth, with 9-11% organic growth rates in recent quarters. **International Market Development**: The company has prioritized international expansion, particularly in Europe, where it has achieved double-digit growth rates. International CAG diagnostic recurring revenue grew 12% organically in 2024, significantly outpacing the 4% growth in the US market. This geographic diversification helps offset slower growth in the mature US veterinary market. **Market Adaptation Strategies**: Facing headwinds from declining veterinary clinic visits (approximately 2% decline expected to continue), IDEXX has focused on increasing diagnostic utilization per visit and expanding into wellness and preventive care testing. The company maintains high customer retention rates above 97% while navigating macro economic pressures affecting pet owner spending and veterinary clinic capacity constraints.
IDXX company profile · for informational purposes only — not investment advice.
Track IDXX with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free